Sotrovimab, the anti-viral medicine for COVID-19, is 100 per cent effective in preventing death, according to the latest study results released by MoHAP.
It showed that 97 per cent of the recipients recovered within 14 days and prevented ICU admission in 99 per cent of the cases.
The study was carried out between June 30 and July 13 in collaboration with the Abu Dhabi Department of Health and Dubai Health Authority (DHA).
Over 6,100 patients were given the anti-viral medicine, of which 52 per cent were aged 50 or above and had multiple pre-existing medical conditions.
The UAE was one of the first countries to receive the shipment of the medicine and had approved its use in June.


UAE hails Yemen prisoner swap agreement as key humanitarian step
UAE reinforces global humanitarian leadership
Dubai Police warn against fake ticket scams
Egyptian scientist wins UAE's 'Great Arab Minds' award in medicine
UAE contributes $2 million to support healthcare in Sudan
UAE ministry closes domestic workers service office, revokes license
Dubai launches transport data lab to improve traffic management
Dubai Police launch campaign to raise awareness on women's protection rights
UAE condemns armed attack in northwestern Pakistan
H.H. Sheikh Hamdan commends Dubai Health's role in advancing global standards
UAE President holds bilateral talks with King of Malaysia
Dubai Police urge caution after fatigue-related accident
CBUAE revokes exchange house licence, issues hefty fine
Jebel Jais temporarily closes after recent unstable weather conditions
UAE President stresses on Gaza ceasefire with Norway PM
Dubai unveils region's first integrated recreational vehicle route
RTA deploys drones to inspect Dubai Metro tunnels
Emergency calls surge amid weather fluctuations in Dubai
UAE President discusses strategic partnership with Elon Musk
Abu Dhabi warns community on fire hazards during winter
